Former Aperio Executive and Digital Pathology Market Expert, Dr. Martin Stuart, Joins Definiens Executive Team
Martin Stuart, a former Senior Vice President and General Manager of Aperio, is one of the most influential leaders in the Digital Pathology industry. He has more than 25 years of experience in international sales and marketing, specializing in the introduction of new and disruptive technologies. In his previous global sales and marketing position he was a key driver in making Aperio the leading provider of digital pathology, with more than 850 deployed slide scanner systems in more than 30 countries. Prior to Aperio, Stuart was Global Vice President of Sales and Services for Entropia Inc., a desktop grid computing company focused on the Life Sciences market.
"I’m excited to join the market leader in Quantitative Digital Pathology" comments Stuart. "Image analysis is a major driver of adoption and I’m extremely impressed by the results customers are getting by deploying Definiens products and solutions. There is enormous demand for solutions that help pathologists deal with the increasing complexities of their discipline as they support the transition to personalized medicine. I see Definiens as best positioned to address this demand by providing comprehensive decision support solutions."
"We are extremely pleased to have Martin join Definiens at a time when demand for our products is growing rapidly" says Thomas Heydler, CEO of Definiens. "His executive experience in the digital pathology business coupled with a profound domain background makes him an ideal fit for our team. With this appointment we will significantly increase both our Life Sciences and our Healthcare Business."
Definiens is a leading Health Image Intelligence™ company that develops software solutions for biomedical image analysis, data mining and clinical decision support. The company’s software analyzes images from cell-based assays, whole tissue slides and full body scans and allows users to correlate this information with data derived from other sources, supporting better decisions in research, diagnostics and therapy. By automating analysis workflows and generating new knowledge, Definiens provides pharmaceutical and biotechnology companies, research institutions, clinical service organizations and medical professionals with deeper insights, faster results and better decision support. Harnessing the power of image intelligence, Definiens supports personalized medicine and aims to significantly improve the quality of patients’ lives.
Definiens is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at www.definiens.com.